{"entity":{"type":"insider","cik":"0001929300","url":"/insider/0001929300","json_url":"/insider/0001929300.json","name":"Gilad Oren","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":6,"first":"2024-03-14","last":"2026-02-02","span_basis":"filed_date"},"name_variants":[{"name":"Gilad Oren","source":"filing","n_filings":6,"first_seen":"2024-03-14","last_seen":"2026-02-02"}],"transactions":[{"id":5808087,"accession":"0001104659-26-009206","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-009206","line_url":"/filing/0001104659-26-009206#line-1","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":28100.0,"shares_display":"28,100","price_per_share":0.89,"price_display":"0.89","price_state":"stated","total_value":25009.0,"total_display":"25,009.00","total_whole":"25,009","shares_owned_after":373720.0,"shares_owned_after_display":"373,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-30","filed_date":"2026-02-02","scope":"insider"},{"id":5128604,"accession":"0001104659-25-031991","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-031991","line_url":"/filing/0001104659-25-031991","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5500.0,"shares_display":"5,500","price_per_share":1.83822,"price_display":"1.84","price_state":"stated","total_value":10110.21,"total_display":"10,110.21","total_whole":"10,110","shares_owned_after":343123.0,"shares_owned_after_display":"343,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-03","filed_date":"2025-04-04","scope":"insider","n_lines":2},{"id":2354223,"accession":"0001104659-24-111031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-111031","line_url":"/filing/0001104659-24-111031#line-1","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":3.915,"price_display":"3.92","price_state":"stated","total_value":1957.5,"total_display":"1,957.50","total_whole":"1,958","shares_owned_after":333395.0,"shares_owned_after_display":"333,395","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-23","filed_date":"2024-10-24","scope":"insider"},{"id":2964113,"accession":"0001104659-24-108964","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-108964","line_url":"/filing/0001104659-24-108964#line-1","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250.0,"shares_display":"250","price_per_share":2.9,"price_display":"2.90","price_state":"stated","total_value":725.0,"total_display":"725.00","total_whole":"725","shares_owned_after":332895.0,"shares_owned_after_display":"332,895","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-16","scope":"insider"},{"id":3268741,"accession":"0001104659-24-108375","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-108375","line_url":"/filing/0001104659-24-108375#line-2","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":2.59,"price_display":"2.59","price_state":"stated","total_value":2590.0,"total_display":"2,590.00","total_whole":"2,590","shares_owned_after":332645.0,"shares_owned_after_display":"332,645","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-14","filed_date":"2024-10-15","scope":"insider"},{"id":3268737,"accession":"0001104659-24-108375","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-108375","line_url":"/filing/0001104659-24-108375#line-1","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President/CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150.0,"shares_display":"150","price_per_share":2.54,"price_display":"2.54","price_state":"stated","total_value":381.0,"total_display":"381.00","total_whole":"381","shares_owned_after":331645.0,"shares_owned_after_display":"331,645","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-10","filed_date":"2024-10-15","scope":"insider"},{"id":2212824,"accession":"0001104659-24-034670","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-034670","line_url":"/filing/0001104659-24-034670#line-1","is_derivative":false,"issuer_cik":"0001781983","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001781983","owner_cik":"0001929300","owner_name":"Gilad Oren","owner_display_name":"Gilad Oren","owner_url":"/insider/0001929300","role":"Director, Officer (President, CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":7.29,"price_display":"7.29","price_state":"stated","total_value":14580.0,"total_display":"14,580.00","total_whole":"14,580","shares_owned_after":324770.0,"shares_owned_after_display":"324,770","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001781983","name":"Aprea Therapeutics, Inc.","url":"/issuer/0001781983","role":"Director, Officer (President/CEO)","n_filings":6,"first_seen":"2024-03-14","last_seen":"2026-02-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001929300","retrieved_at":"2026-08-27T12:02:45+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}